Results by group168

Each measurement the trial posted, group by group, in the words and numbers it posted.

161 to 168 of 168

Outcome	Group	Value	Spread	Units
Baseline MRI Variables - LV Mass/End-diastolic Volume	Verinurad 9 mg+Febuxostat 80 mg	0.696	Standard Deviation 0.1437	g/mL
Baseline MRI Variables - LV Mass/End-diastolic Volume	Placebo	0.687	Standard Deviation 0.1163	g/mL
Baseline MRI Variables - LV Stroke Volume	Verinurad 9 mg+Febuxostat 80 mg	95.05	Standard Deviation 19.327	mL
Baseline MRI Variables - LV Stroke Volume	Placebo	96.86	Standard Deviation 21.286	mL
Baseline Flow Mediated Dilatation (Reactive Hyperemia)	Verinurad 9 mg+Febuxostat 80 mg	60.4	Standard Deviation 28.76	Units on a scale
Baseline Flow Mediated Dilatation (Reactive Hyperemia)	Placebo	60.6	Standard Deviation 30.90	Units on a scale
Urinary Albumin to Creatinine Ratio (UACR)	Verinurad 9 mg+Febuxostat 80 mg	-38.40	95% Confidence Interval -58.051 to -9.535	Precent change
Urinary Albumin to Creatinine Ratio (UACR)	Placebo	21.40	95% Confidence Interval -18.948 to 81.829	Precent change

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03118739/results?page=9